Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Carcinoma, Basal Cell 4Pleural Diseases 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sezary Syndrome 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Pain 1Non-Muscle Invasive Bladder Neoplasms 1Mycosis Fungoides 1Mesothelioma, Malignant 1Lymphoma, T-Cell, Cutaneous 1Leukoplakia, Oral 1Esthesioneuroblastoma, Olfactory 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1Basal Cell Nevus Syndrome 1Adenocarcinoma, Follicular 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 26Nivolumab 18enfortumab vedotin 7avelumab 6atezolizumab 6Ipilimumab 6Magnetic Resonance Spectroscopy 5fludarabine 4cabozantinib 4Gemcitabine 4Cyclophosphamide 4Carboplatin 4Specimen Handling 3Interleukin-2 3Docetaxel 3130-nm albumin-bound paclitaxel 3aldesleukin 2Platinum 2Pemetrexed 2Paclitaxel 2Oxaliplatin 2Immunoglobulin G 2Fluorodeoxyglucose F18 2FAPI-46 2Disulfides 2Cisplatin 2Albumin-Bound Paclitaxel 2vinflunine 1veliparib 1valrubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Transitional Cell × 1-phenyl-3,3-dimethyltriazene × Clear all
NCT03053635 2018-08-20

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

TheralaseĀ® Technologies Inc.

Phase 1 Completed
6 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚔